# Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

> **NCT06429150** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen Geno-Immune Medical Institute** · enrollment: 20 (estimated)

## Conditions studied

- Multiple Myeloma
- Plasmacytoma

## Interventions

- **BIOLOGICAL:** CAR-T cells

## Key facts

- **NCT ID:** NCT06429150
- **Lead sponsor:** Shenzhen Geno-Immune Medical Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-11
- **Primary completion:** 2027-07-11
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429150, "Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06429150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*